Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KSW signed 25 Millions contracts in the last 7 days and their market cap is only $45 MM with total back log over $ 120 MM ,no debt and cash per share 2.15.
who 's selling with 2 big news???
KSW Awarded Prestigious West Side ProjectLast update: 7/12/2007 11:13:27 AMLONG ISLAND CITY, N.Y., Jul 12, 2007 (BUSINESS WIRE) -- KSW, Inc. (KSW) announced today that it has been awarded a contract, valued at approximately $9,200,000, to furnish the HVAC systems for a new mixed use project at 808 Columbus Avenue in Manhattan. The project, which extends from 97th to 100th Streets, includes a 359 unit apartment tower situated atop 220,000 square feet of retail space. Construction is scheduled to begin in September, 2007. KSW's Chairman, Floyd Warkol, commented that "Both the developer and the construction manager are repeat clients. The developer is headed by The Chetrit Group, for whom KSW is currently performing work at an apartment building at 1510 Second Avenue. KSW has worked on several projects for the construction manager, Gotham Construction Company, including the large apartment building at 10 West End Avenue currently near completion." About KSW KSW, Inc., through its wholly-owned subsidiary, KSW Mechanical Services, Inc., furnishes and installs heating, ventilating and air conditioning (HVAC) systems and process piping systems for institutional, industrial, commercial, high-rise residential and public works projects. KSW Mechanical Services, Inc. also acts as Trade Manager on larger construction projects, such as the New York Presbyterian Cardiovascular Center.
KSW Awarded Prestigious West Side ProjectLast update: 7/12/2007 11:13:27 AMLONG ISLAND CITY, N.Y., Jul 12, 2007 (BUSINESS WIRE) -- KSW, Inc. (KSW) announced today that it has been awarded a contract, valued at approximately $9,200,000, to furnish the HVAC systems for a new mixed use project at 808 Columbus Avenue in Manhattan. The project, which extends from 97th to 100th Streets, includes a 359 unit apartment tower situated atop 220,000 square feet of retail space. Construction is scheduled to begin in September, 2007. KSW's Chairman, Floyd Warkol, commented that "Both the developer and the construction manager are repeat clients. The developer is headed by The Chetrit Group, for whom KSW is currently performing work at an apartment building at 1510 Second Avenue. KSW has worked on several projects for the construction manager, Gotham Construction Company, including the large apartment building at 10 West End Avenue currently near completion." About KSW KSW, Inc., through its wholly-owned subsidiary, KSW Mechanical Services, Inc., furnishes and installs heating, ventilating and air conditioning (HVAC) systems and process piping systems for institutional, industrial, commercial, high-rise residential and public works projects. KSW Mechanical Services, Inc. also acts as Trade Manager on larger construction projects, such as the New York Presbyterian Cardiovascular Center.
kSW KSW Awarded Prestigious West Side ProjectLast update: 7/12/2007 11:13:27 AMLONG ISLAND CITY, N.Y., Jul 12, 2007 (BUSINESS WIRE) -- KSW, Inc. (KSW) announced today that it has been awarded a contract, valued at approximately $9,200,000, to furnish the HVAC systems for a new mixed use project at 808 Columbus Avenue in Manhattan. The project, which extends from 97th to 100th Streets, includes a 359 unit apartment tower situated atop 220,000 square feet of retail space. Construction is scheduled to begin in September, 2007. KSW's Chairman, Floyd Warkol, commented that "Both the developer and the construction manager are repeat clients. The developer is headed by The Chetrit Group, for whom KSW is currently performing work at an apartment building at 1510 Second Avenue. KSW has worked on several projects for the construction manager, Gotham Construction Company, including the large apartment building at 10 West End Avenue currently near completion." About KSW KSW, Inc., through its wholly-owned subsidiary, KSW Mechanical Services, Inc., furnishes and installs heating, ventilating and air conditioning (HVAC) systems and process piping systems for institutional, industrial, commercial, high-rise residential and public works projects. KSW Mechanical Services, Inc. also acts as Trade Manager on larger construction projects, such as the New York Presbyterian Cardiovascular Center.
SMTX --YEp,they booked approx $16 MM last Q and it was their slowest.The 15 MM contract would put their back log north of 120 MM and not counting the small unreported contracts under 9 MM .This stock has a double written all over it.IMO
KSW Awarded $15,6000 MM Two New Brooklyn Waterfront Projects
Monday July 2, 8:30 am ET
LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--KSW, Inc. (AMEX: KSW - News) announced today that it has been selected as the HVAC contractor for two new luxury condominium projects on the Brooklyn waterfront being developed by a group headed by Jeffrey Levine, a major New York developer. The contracts total approximately $15,600,000. The Company will now be working on four projects in the Brooklyn waterfront area.
ADVERTISEMENT
Chairman of the Board, Floyd Warkol, commented: "We are gratified to be awarded these new projects, having just recently completed work on Jeff's 42-story luxury condominium building at 325 Fifth Avenue in Manhattan. Building working relationships with respected developers is the key to KSW's success
http://biz.yahoo.com/bw/070702/20070702005218.html?.v=1
KSW Awarded $15,6000 MM Two New Brooklyn Waterfront Projects
Monday July 2, 8:30 am ET
LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--KSW, Inc. (AMEX: KSW - News) announced today that it has been selected as the HVAC contractor for two new luxury condominium projects on the Brooklyn waterfront being developed by a group headed by Jeffrey Levine, a major New York developer. The contracts total approximately $15,600,000. The Company will now be working on four projects in the Brooklyn waterfront area.
ADVERTISEMENT
Chairman of the Board, Floyd Warkol, commented: "We are gratified to be awarded these new projects, having just recently completed work on Jeff's 42-story luxury condominium building at 325 Fifth Avenue in Manhattan. Building working relationships with respected developers is the key to KSW's success
http://biz.yahoo.com/bw/070702/20070702005218.html?.v=1
KSW Awarded $15,6000 MM Two New Brooklyn Waterfront Projects
Monday July 2, 8:30 am ET
LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--KSW, Inc. (AMEX: KSW - News) announced today that it has been selected as the HVAC contractor for two new luxury condominium projects on the Brooklyn waterfront being developed by a group headed by Jeffrey Levine, a major New York developer. The contracts total approximately $15,600,000. The Company will now be working on four projects in the Brooklyn waterfront area.
ADVERTISEMENT
Chairman of the Board, Floyd Warkol, commented: "We are gratified to be awarded these new projects, having just recently completed work on Jeff's 42-story luxury condominium building at 325 Fifth Avenue in Manhattan. Building working relationships with respected developers is the key to KSW's success
http://biz.yahoo.com/bw/070702/20070702005218.html?.v=1
SMTX is a super undervalued turn around play.This baby will be a double digits stock within 12 months.IMO
CRNT -BBOTCS,I'm in since the low 5.They didn't lose $$ the last 4 th Q.They had 1 time charge to get out of the subsidizing from the Israel gov.
SMTX is another excellent comp,it's a turn around play.It's one of the cheapest stock on the NASD..Do the DD and thank me later.I'm heavily in both .GLTY
CRNT beats by a penny and raised rev guidance.
Ceragon Networks(R) Reports Record First Quarter 2007 Financial ResultsLast update: 4/30/2007 8:01:00 AM"Strong Demand From Emerging Markets Generates Higher Revenues and Bookings" TEL AVIV, Israel, April 30, 2007 /PRNewswire-FirstCall via COMTEX/ -- Ceragon Networks Ltd. (CRNT), , a leading provider of high-capacity wireless backhaul solutions, today reported results for the first quarter which ended March 31, 2007. Revenues for the first quarter of 2007 were $33.9 million, up 59% from $21.3 million for the first quarter of 2006 and 3% from $32.9 million in the fourth quarter of 2006. Net income in accordance with Generally Accepted Accounting Principles (GAAP) for the first quarter of 2007 was $2.6 million or $0.10 per basic share and $0.09 per diluted share. On a non-GAAP basis net income for the first quarter, excluding $390,000 of equity-based compensation expenses, was $3.0 million, or $0.11 per basic share and $0.10 per diluted share, compared to non-GAAP net income of $1.0 million, or $0.04 per basic and diluted share in the first quarter of 2006. (Refer to the accompanying financial table for reconciliation of GAAP financial information to non-GAAP.) Gross margin on a GAAP basis in the first quarter of 2007 was 36.3% of revenues. On a non-GAAP basis gross margin was 36.4% of revenues. Cash and cash equivalents, short- and long-term deposits and short- and long-term marketable securities totaled $29.5 million at March 31, 2007. "We are pleased to report that we began the year with record results and strong bookings," said Ira Palti, President and CEO of Ceragon. "Based on strong demand from emerging markets, particularly in the Asia Pacific region, we are revising our revenue growth target for 2007 upward from an increase of around 25% to an increase of about 30% over 2006 ." "The need for more high-capacity wireless backhaul is being fueled by growing demand for mobile data services in the developed world, combined with growth in cellular subscribers in emerging economies. We are also benefiting from the migration to all-IP networks and broadband connectivity via WiMAX. We are leading the market with field-proven high-capacity solutions including a native IP solution as well as a multi-service solution combining native IP with native TDM capabilities on a single flexible platform. In addition to our continuous cost reduction program, we are focused on increasing our production capacity and shortening delivery times in order to address the widespread demand," said Palti. A conference call discussing Ceragon's results for the first quarter of 2007, business conditions, and outlook, will take place today, April 30, 2007, at 9:00 a.m. (EDT). Investors can join the Company's teleconference by calling (800)-230-1766 or international (612)-332-0725 at 8:50 a.m. EDT. Investors are also invited to listen to the call live via the Internet by accessing Ceragon Networks' website at the investors' page: , selecting the webcast link, and following the registration instructions. If you are unable to join us live, the replay numbers are: (800)-475-6701 or international (320)-365-3844. A replay of both the call and the webcast link will be accessible through May 30, 2007. About Ceragon Networks Ltd. Ceragon Networks Ltd. (NASDAQ and TASE: CRNT) is a leading provider of high-capacity wireless backhaul solutions for cellular and fixed wireless operators, enterprises and government organizations. Ceragon's modular FibeAir(R) product family is recognized as the gold standard for backhaul transmission and is also one of the top solutions chosen by cellular operators for SONET/SDH rings. A scalable, future-proof solution for wireless transport of broadband services, FibeAir operates across multiple frequencies for IP and SONET/SDH protocols, supporting the emerging needs of next-generation networks that are evolving to all-IP based services, including triple-play. It leads the market in IP backhaul, offering a unique, native IP solution that provides the efficient, robust connectivity required for WiFi, WiMAX and converged networks. Ceragon supports its growing base of more than 180 customers in 70 countries by operating an extensive sales network comprising 17 offices and numerous partners located around the world. More information is available at . Ceragon Networks(R), CeraView(R), FibeAir(R) and the FibeAir(R) design mark are registered trademarks of Ceragon Networks Ltd., and Ceragon(TM), PolyView(TM), ConfigAir(TM), CeraMon(TM), EtherAir(TM), QuickAir(TM), QuickAir Partner Program(TM), QuickAir Partner Certification Program(TM), QuickAir Partner Zone(TM), EncryptAir(TM) and Microwave Fiber(TM) are trademarks of Ceragon Networks Ltd.
CRNT beats by a penny and raised rev guidance.
Ceragon Networks(R) Reports Record First Quarter 2007 Financial ResultsLast update: 4/30/2007 8:01:00 AM"Strong Demand From Emerging Markets Generates Higher Revenues and Bookings" TEL AVIV, Israel, April 30, 2007 /PRNewswire-FirstCall via COMTEX/ -- Ceragon Networks Ltd. (CRNT), , a leading provider of high-capacity wireless backhaul solutions, today reported results for the first quarter which ended March 31, 2007. Revenues for the first quarter of 2007 were $33.9 million, up 59% from $21.3 million for the first quarter of 2006 and 3% from $32.9 million in the fourth quarter of 2006. Net income in accordance with Generally Accepted Accounting Principles (GAAP) for the first quarter of 2007 was $2.6 million or $0.10 per basic share and $0.09 per diluted share. On a non-GAAP basis net income for the first quarter, excluding $390,000 of equity-based compensation expenses, was $3.0 million, or $0.11 per basic share and $0.10 per diluted share, compared to non-GAAP net income of $1.0 million, or $0.04 per basic and diluted share in the first quarter of 2006. (Refer to the accompanying financial table for reconciliation of GAAP financial information to non-GAAP.) Gross margin on a GAAP basis in the first quarter of 2007 was 36.3% of revenues. On a non-GAAP basis gross margin was 36.4% of revenues. Cash and cash equivalents, short- and long-term deposits and short- and long-term marketable securities totaled $29.5 million at March 31, 2007. "We are pleased to report that we began the year with record results and strong bookings," said Ira Palti, President and CEO of Ceragon. "Based on strong demand from emerging markets, particularly in the Asia Pacific region, we are revising our revenue growth target for 2007 upward from an increase of around 25% to an increase of about 30% over 2006 ." "The need for more high-capacity wireless backhaul is being fueled by growing demand for mobile data services in the developed world, combined with growth in cellular subscribers in emerging economies. We are also benefiting from the migration to all-IP networks and broadband connectivity via WiMAX. We are leading the market with field-proven high-capacity solutions including a native IP solution as well as a multi-service solution combining native IP with native TDM capabilities on a single flexible platform. In addition to our continuous cost reduction program, we are focused on increasing our production capacity and shortening delivery times in order to address the widespread demand," said Palti. A conference call discussing Ceragon's results for the first quarter of 2007, business conditions, and outlook, will take place today, April 30, 2007, at 9:00 a.m. (EDT). Investors can join the Company's teleconference by calling (800)-230-1766 or international (612)-332-0725 at 8:50 a.m. EDT. Investors are also invited to listen to the call live via the Internet by accessing Ceragon Networks' website at the investors' page: , selecting the webcast link, and following the registration instructions. If you are unable to join us live, the replay numbers are: (800)-475-6701 or international (320)-365-3844. A replay of both the call and the webcast link will be accessible through May 30, 2007. About Ceragon Networks Ltd. Ceragon Networks Ltd. (NASDAQ and TASE: CRNT) is a leading provider of high-capacity wireless backhaul solutions for cellular and fixed wireless operators, enterprises and government organizations. Ceragon's modular FibeAir(R) product family is recognized as the gold standard for backhaul transmission and is also one of the top solutions chosen by cellular operators for SONET/SDH rings. A scalable, future-proof solution for wireless transport of broadband services, FibeAir operates across multiple frequencies for IP and SONET/SDH protocols, supporting the emerging needs of next-generation networks that are evolving to all-IP based services, including triple-play. It leads the market in IP backhaul, offering a unique, native IP solution that provides the efficient, robust connectivity required for WiFi, WiMAX and converged networks. Ceragon supports its growing base of more than 180 customers in 70 countries by operating an extensive sales network comprising 17 offices and numerous partners located around the world. More information is available at . Ceragon Networks(R), CeraView(R), FibeAir(R) and the FibeAir(R) design mark are registered trademarks of Ceragon Networks Ltd., and Ceragon(TM), PolyView(TM), ConfigAir(TM), CeraMon(TM), EtherAir(TM), QuickAir(TM), QuickAir Partner Program(TM), QuickAir Partner Certification Program(TM), QuickAir Partner Zone(TM), EncryptAir(TM) and Microwave Fiber(TM) are trademarks of Ceragon Networks Ltd.
CRNT beats by a penny and raised rev guidance.
Ceragon Networks(R) Reports Record First Quarter 2007 Financial ResultsLast update: 4/30/2007 8:01:00 AM"Strong Demand From Emerging Markets Generates Higher Revenues and Bookings" TEL AVIV, Israel, April 30, 2007 /PRNewswire-FirstCall via COMTEX/ -- Ceragon Networks Ltd. (CRNT), , a leading provider of high-capacity wireless backhaul solutions, today reported results for the first quarter which ended March 31, 2007. Revenues for the first quarter of 2007 were $33.9 million, up 59% from $21.3 million for the first quarter of 2006 and 3% from $32.9 million in the fourth quarter of 2006. Net income in accordance with Generally Accepted Accounting Principles (GAAP) for the first quarter of 2007 was $2.6 million or $0.10 per basic share and $0.09 per diluted share. On a non-GAAP basis net income for the first quarter, excluding $390,000 of equity-based compensation expenses, was $3.0 million, or $0.11 per basic share and $0.10 per diluted share, compared to non-GAAP net income of $1.0 million, or $0.04 per basic and diluted share in the first quarter of 2006. (Refer to the accompanying financial table for reconciliation of GAAP financial information to non-GAAP.) Gross margin on a GAAP basis in the first quarter of 2007 was 36.3% of revenues. On a non-GAAP basis gross margin was 36.4% of revenues. Cash and cash equivalents, short- and long-term deposits and short- and long-term marketable securities totaled $29.5 million at March 31, 2007. "We are pleased to report that we began the year with record results and strong bookings," said Ira Palti, President and CEO of Ceragon. "Based on strong demand from emerging markets, particularly in the Asia Pacific region, we are revising our revenue growth target for 2007 upward from an increase of around 25% to an increase of about 30% over 2006 ." "The need for more high-capacity wireless backhaul is being fueled by growing demand for mobile data services in the developed world, combined with growth in cellular subscribers in emerging economies. We are also benefiting from the migration to all-IP networks and broadband connectivity via WiMAX. We are leading the market with field-proven high-capacity solutions including a native IP solution as well as a multi-service solution combining native IP with native TDM capabilities on a single flexible platform. In addition to our continuous cost reduction program, we are focused on increasing our production capacity and shortening delivery times in order to address the widespread demand," said Palti. A conference call discussing Ceragon's results for the first quarter of 2007, business conditions, and outlook, will take place today, April 30, 2007, at 9:00 a.m. (EDT). Investors can join the Company's teleconference by calling (800)-230-1766 or international (612)-332-0725 at 8:50 a.m. EDT. Investors are also invited to listen to the call live via the Internet by accessing Ceragon Networks' website at the investors' page: , selecting the webcast link, and following the registration instructions. If you are unable to join us live, the replay numbers are: (800)-475-6701 or international (320)-365-3844. A replay of both the call and the webcast link will be accessible through May 30, 2007. About Ceragon Networks Ltd. Ceragon Networks Ltd. (NASDAQ and TASE: CRNT) is a leading provider of high-capacity wireless backhaul solutions for cellular and fixed wireless operators, enterprises and government organizations. Ceragon's modular FibeAir(R) product family is recognized as the gold standard for backhaul transmission and is also one of the top solutions chosen by cellular operators for SONET/SDH rings. A scalable, future-proof solution for wireless transport of broadband services, FibeAir operates across multiple frequencies for IP and SONET/SDH protocols, supporting the emerging needs of next-generation networks that are evolving to all-IP based services, including triple-play. It leads the market in IP backhaul, offering a unique, native IP solution that provides the efficient, robust connectivity required for WiFi, WiMAX and converged networks. Ceragon supports its growing base of more than 180 customers in 70 countries by operating an extensive sales network comprising 17 offices and numerous partners located around the world. More information is available at . Ceragon Networks(R), CeraView(R), FibeAir(R) and the FibeAir(R) design mark are registered trademarks of Ceragon Networks Ltd., and Ceragon(TM), PolyView(TM), ConfigAir(TM), CeraMon(TM), EtherAir(TM), QuickAir(TM), QuickAir Partner Program(TM), QuickAir Partner Certification Program(TM), QuickAir Partner Zone(TM), EncryptAir(TM) and Microwave Fiber(TM) are trademarks of Ceragon Networks Ltd.
NEWS!!!
Access Pharmaceuticals Announces Expansion of ProLindac(TM) Clinical Trial SitesLast update: 4/27/2007 10:27:00 AMDALLAS, April 27, 2007 /PRNewswire-FirstCall via COMTEX/ -- ACCESS PHARMACEUTICALS, INC. (ACCP) announced today that it has continued to expand the number of clinical trial sites for its on-going Phase 2 trial of ProLindac in patients with recurrent platinum-sensitive ovarian cancer. The number of sites opened has now reached 11, up from two initial sites when the trial was commenced last year. The additional sites allow for the potential of more rapid patient accrual. "We are pleased with the increase in hospitals that are interested in participating in our ProLindac ovarian cancer trial," said Stephen R. Seiler, Access' Chief Executive Officer. "The expanded number of sites also gives us the advantage of being able to draw from a larger potential patient population for trial enrolment." ProLindac, is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes ProLindac's unique molecular design potentially could eliminate some of the toxic neurological side effects seen in the currently marketed DACH platinum, oxaliplatin, which has sales in excess of $2 billion. In a Phase 1 clinical study, at least five times more DACH platinum could be administered to patients with ProLindac(TM) than oxaliplatin before the
KSW is ready to POP.
KSW -They made .18 4 th Quarter 2006 , the earnings went up 80 % from .10 last 4 th Quarter 2005.
AUTHORIZED SHARES 100,000,000
OUTSTANDING SHARES 5.8 MILLION
FLOAT------------- 3.73 MILLION
CASH 14,085,000 as of 3-14-07
NO DEBT
BACK LOG 110 Millions
http://www.smallcapsleepers.com/samples/...
READ their 10 K .
http://finance.yahoo.com/q?d=t&s=KSW
They generated cash to $14,085,000, an increase
of $8,886,000 from the $5,199,000 reported as of December 31, 2005.The market cap is only 38 Millions dollars ,that's only 1/2 of their annual revenues.
They have 2.54 cash per share .The market is only valued their business 4 dollars per share .They have 110 millions back log .
The P/E is only around 6 if you substract the cash .
Annual earning .18 X 4 Q = .72
Share price 6.44 - cash (2.54)= 3.9 : .72 = PE around 6 the average PE for engineering/construction is 20 .KSW should be in the 10 -15 dollars per share .That's a 100 % from 6.44. The trading float is very low and the big institutions have been buying .They even have a 12 millions contract with Donal Trump Hotel project.
http://www.nasdaq.com/asp/Holdings.asp?m...
KSW is ready to pop.
KSW They made .18 4 th Quarter 2006 , the earnings went up 80 % from .10 last 4 th Quarter 2005.
AUTHORIZED SHARES 100,000,000
OUTSTANDING SHARES 5.8 MILLION
FLOAT------------- 3.73 MILLION
CASH 14,085,000 as of 3-14-07
NO DEBT
BACK LOG 110 Millions
http://www.smallcapsleepers.com/samples/...
READ their 10 K .
http://finance.yahoo.com/q?d=t&s=KSW
They generated cash to $14,085,000, an increase
of $8,886,000 from the $5,199,000 reported as of December 31, 2005.The market cap is only 38 Millions dollars ,that's only 1/2 of their annual revenues.
They have 2.54 cash per share .The market is only valued their business 4 dollars per share .They have 110 millions back log .
The P/E is only around 6 if you substract the cash .
Annual earning .18 X 4 Q = .72
Share price 6.44 - cash (2.54)= 3.9 : .72 = PE around 6 the average PE for engineering/construction is 20 .KSW should be in the 10 -15 dollars per share .That's a 100 % from 6.44. The trading float is very low and the big institutions have been buying .They even have a 12 millions contract with Donal Trump Hotel project.
http://www.nasdaq.com/asp/Holdings.asp?m...
"If " = SPECULATE ,lol.
WE all know their earnings from the previous Q are bad.The new managements took over and changed their business model only a few months ago.Let's see how they'll do in the next few Q.
If they really own 15% of the shenzen exchange then $1 PPS is the low estimate.IMO
CC tomorrow .
Access Pharmaceuticals Announces Conference Call to Discuss Recent Acquisition NewsLast update: 2/21/2007 2:48:00 PMDALLAS, Feb 21, 2007 /PRNewswire-FirstCall via COMTEX/ -- Access Pharmaceuticals, Inc. (ACCP) announced today that it will conduct a conference call to discuss its proposed acquisition of Somanta Pharmaceuticals with the investment community. The call will take place on Thursday, February 22, 2007, after the financial markets close at 4:00 pm EST. Mr. Stephen R. Seiler, President and CEO of Access and Dr. Agamemnon Epenetos, CEO of Somanta will co-host the call. Interested parties may participate in the call by dialing (877) 407-8293; international callers dial (201) 689-8349 about 5-10 minutes prior to 4:00 pm EST. The conference call will also be available on replay starting at 7:00 pm EST on February 22, 2007, and ending on March 22, 2007. For the replay, please dial (877) 660-6853 (replay account # 294, replay conference # 232644). The access number for the replay for international callers is (201) 612-7415 (replay account # 294, replay conference # 232644). About Access Pharmaceuticals, Inc. Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on developing and commercializing propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis for which marketing allowance has been granted by the FDA. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals
ACCP -They shaked to weed the weak hands out.IMO
More news !!
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta PharmaceuticalsLast update: 2/21/2007 9:37:00 AMAcquisition of Four Potent Anti-Cancer Compounds, Including Phase 2 Drug Candidate and Experienced Clinical Development Team Positions Access as a Leading Developer of Oncology Therapeutics DALLAS and Irvine, Calif., Feb 21, 2007 /PRNewswire-FirstCall via COMTEX/ -- Access Pharmaceuticals, Inc. (ACCP) and Somanta Pharmaceuticals, Inc. (SMPM) announced today that they have signed a letter of intent for Access to acquire Somanta. Somanta is an Irvine, California based biotechnology company with four novel anti-cancer compounds in development, one of which is currently in Phase 2 clinical trials. Each of Somanta's drug candidates acts by a unique mechanism of action, and has the potential to target a wide range of different cancer types. In addition to its significant product pipeline, Somanta brings an experienced team of clinical development and regulatory professionals who have an established track record of guiding compounds through the FDA and EMEA approval processes. Upon consummation of the acquisition, Somanta's preferred and common shareholders will receive an aggregate of 1.5 million shares of Access common shares which would represent approximately 13% of the combined company assuming the conversion of Access' existing convertible debt under existing terms of conversion. The letter of intent is non-binding. The acquisition is expected to close in the second quarter. "The proposed acquisition of Somanta is very exciting for Access from a number of perspectives," stated Stephen R. Seiler, Access' President and CEO. "Somanta comes with four very interesting anti-cancer compounds, one of which is already in Phase 2 clinical trials. Each compound acts by a novel mode of action, and one represents a novel platform technology. As a result, the combined Access and Somanta will have a broad cancer-focused portfolio which will include one approved product, two drug candidates in Phase 2 trials and three novel and exciting pre-clinical products. Our goal has always been to make Access a leader in the oncology space and this acquisition fills out our product pipeline extremely well." "In addition, the Somanta clinical development team fits well with our current management group," continued Mr. Seiler. "I look forward to leveraging their expertise to assist in accelerating and broadening the clinical program for Access' ProLindac which is in Phase 2 trials in the EU and in the U.S. as well as on our oral insulin program." "The proposed combination of Somanta with Access is highly synergistic," added Agamemnon Epenetos, M.D., Ph.D., Somanta's CEO. "Each company is at a position where the combination makes strategic sense, and the product pipelines and management teams come together very well, with little overlap. I believe the combined product and technology pipeline is extremely exciting, and I look forward to working closely with the Access team to advance both companies' products through the development and regulatory process." About Somanta Somanta Pharmaceuticals is a company focused on the development of novel oncology compounds and anti-cancer agents. Somanta's lead clinical product Sodium Phenylbutyrate (PB) is currently in Phase 2 development. In National Institute of Health sponsored trials, PB has demonstrated the greatest activity in CNS cancers, several of which are "orphan" indications such as Glioblastoma Multiforme. Moreover, promising data has also emerged which suggests PB may be an effective therapy for certain blood cancers and other solid tumors. PB has been well tolerated; its safety profile has generally been established due to its many years of clinical use in pediatrics for inherited urea cycle disorders. Somanta's other drug candidates include Alchemix, Prodrax and Angiolix. Alchemix is pan-target inhibitor that is effective in tumor cells resistant to conventional chemotherapy by targeting and irreversibly binding to DNA. Prodrax, a technology platform, is a novel family of prodrugs that enables compounds to remain inert until they reach the hypoxic region of tumors where they become toxic, thus targeting tumor cells which are typically difficult to kill. Somanta believes Alchemix and Prodrax have the ability to overcome many different pathways of drug resistance, and will be studied in a broad range of cancers including lung, colon, ovarian and renal. Proof-of-principle pre- clinical studies have been completed in both of these compounds, and Phase 1 dose escalation trials are being planned. Additionally, Somanta is developing a humanized monoclonal antibody, Angiolix, which appears to induce cell death selectively to tumor blood vessels using a different mode of action than VEGF- oriented therapies. Somanta has prepared clinical development plans for all preclinical projects. For additional information on Somanta Pharmaceuticals, please visit . About Access
More news !!
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta PharmaceuticalsLast update: 2/21/2007 9:37:00 AMAcquisition of Four Potent Anti-Cancer Compounds, Including Phase 2 Drug Candidate and Experienced Clinical Development Team Positions Access as a Leading Developer of Oncology Therapeutics DALLAS and Irvine, Calif., Feb 21, 2007 /PRNewswire-FirstCall via COMTEX/ -- Access Pharmaceuticals, Inc. (ACCP) and Somanta Pharmaceuticals, Inc. (SMPM) announced today that they have signed a letter of intent for Access to acquire Somanta. Somanta is an Irvine, California based biotechnology company with four novel anti-cancer compounds in development, one of which is currently in Phase 2 clinical trials. Each of Somanta's drug candidates acts by a unique mechanism of action, and has the potential to target a wide range of different cancer types. In addition to its significant product pipeline, Somanta brings an experienced team of clinical development and regulatory professionals who have an established track record of guiding compounds through the FDA and EMEA approval processes. Upon consummation of the acquisition, Somanta's preferred and common shareholders will receive an aggregate of 1.5 million shares of Access common shares which would represent approximately 13% of the combined company assuming the conversion of Access' existing convertible debt under existing terms of conversion. The letter of intent is non-binding. The acquisition is expected to close in the second quarter. "The proposed acquisition of Somanta is very exciting for Access from a number of perspectives," stated Stephen R. Seiler, Access' President and CEO. "Somanta comes with four very interesting anti-cancer compounds, one of which is already in Phase 2 clinical trials. Each compound acts by a novel mode of action, and one represents a novel platform technology. As a result, the combined Access and Somanta will have a broad cancer-focused portfolio which will include one approved product, two drug candidates in Phase 2 trials and three novel and exciting pre-clinical products. Our goal has always been to make Access a leader in the oncology space and this acquisition fills out our product pipeline extremely well." "In addition, the Somanta clinical development team fits well with our current management group," continued Mr. Seiler. "I look forward to leveraging their expertise to assist in accelerating and broadening the clinical program for Access' ProLindac which is in Phase 2 trials in the EU and in the U.S. as well as on our oral insulin program." "The proposed combination of Somanta with Access is highly synergistic," added Agamemnon Epenetos, M.D., Ph.D., Somanta's CEO. "Each company is at a position where the combination makes strategic sense, and the product pipelines and management teams come together very well, with little overlap. I believe the combined product and technology pipeline is extremely exciting, and I look forward to working closely with the Access team to advance both companies' products through the development and regulatory process." About Somanta Somanta Pharmaceuticals is a company focused on the development of novel oncology compounds and anti-cancer agents. Somanta's lead clinical product Sodium Phenylbutyrate (PB) is currently in Phase 2 development. In National Institute of Health sponsored trials, PB has demonstrated the greatest activity in CNS cancers, several of which are "orphan" indications such as Glioblastoma Multiforme. Moreover, promising data has also emerged which suggests PB may be an effective therapy for certain blood cancers and other solid tumors. PB has been well tolerated; its safety profile has generally been established due to its many years of clinical use in pediatrics for inherited urea cycle disorders. Somanta's other drug candidates include Alchemix, Prodrax and Angiolix. Alchemix is pan-target inhibitor that is effective in tumor cells resistant to conventional chemotherapy by targeting and irreversibly binding to DNA. Prodrax, a technology platform, is a novel family of prodrugs that enables compounds to remain inert until they reach the hypoxic region of tumors where they become toxic, thus targeting tumor cells which are typically difficult to kill. Somanta believes Alchemix and Prodrax have the ability to overcome many different pathways of drug resistance, and will be studied in a broad range of cancers including lung, colon, ovarian and renal. Proof-of-principle pre- clinical studies have been completed in both of these compounds, and Phase 1 dose escalation trials are being planned. Additionally, Somanta is developing a humanized monoclonal antibody, Angiolix, which appears to induce cell death selectively to tumor blood vessels using a different mode of action than VEGF- oriented therapies. Somanta has prepared clinical development plans for all preclinical projects. For additional information on Somanta Pharmaceuticals, please visit . About Access
ACCP Access Pharmaceuticals Announces Presentation of ProLindac(TM) Data at International Conference
DALLAS, Feb. 21 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc.
(OTC Bulletin Board: ACCP) announced today that recent clinical data for
ProLindac(TM), its novel DACH platinum polymer prodrug, is being presented
at the International Symposium on Polymer Therapeutics at the Freie
Universitat Berlin, in Germany. Following encouraging Phase I clinical
results, ProLindac(TM) is currently in two Phase II studies.
The symposium presentation, given by David P. Nowotnik, Ph.D., Access'
Senior Vice President, Research and Development, is entitled "Results of
preclinical and clinical studies on ProLindac(TM) (AP5346), a DACH-platinum
HPMA polymer prodrug", and provides an overview of the development of this
product to-date. ProLindac(TM) has been shown to be active in a wide
variety of solid tumors in both preclinical models and in human trials. The
Company believes that ProLindac(TM)'s unique molecular design potentially
could eliminate some of the toxic neurological side effects seen in
currently marketed DACH platinums. The Company is currently enrolling
patients in two Phase II clinical trials, one in ovarian cancer and the
other in head and neck cancer, and plans to initiate one or more additional
Phase II trials, including one in colorectal cancer in 2007.
"On the behalf of my colleagues at Access, I am pleased to be
discussing preclinical and clinical studies on ProLindac(TM), which has the
potential to be an effective new polymer-based therapeutic agent for cancer
patients. Access' presence at this international symposium, focused
specifically on polymer therapeutics, yields great recognition for our lead
drug candidate ProLindac(TM), especially among the best and brightest minds
within our industry," commented Dr. Nowotnik.
It needs to built a base here and weeds out the weak hands for the next leg up.IMO
Agree ..it may get there sooner if they get another licensed deal in the US.
I'm adding more .
Wow !!It's falling off the cliff now.They will weed out the weak hands for the next leg up.IMO
Unfortunaly View is making sure we're not going too ;-(.
View is crashing the party again.
I missed that .Thanks
We'll just have to wait what's their story .
It's not?? It said right there 2-14.
14-Feb-2007
Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
Overview
The Company believes that the People's Republic of China represents a dynamic emerging world market whose role in the global economy is increasing steadily. China's economic growth rate, measured by its gross domestic product, has consistently been higher than 7% over the past 10 years. This economic growth is attributable to many factors, including investment in the country's infrastructure, increased privatization of businesses and an abundant source of labor.
They filed 10Q.I don't see where they said they own 15% of Shenzhen.
http://biz.yahoo.com/e/070214/imot.ob10qsb.html
Thanks.
I got another 35K @ .275
Added another 1 k 10.30 .GO ACCP
ACCP -If you compare it(MC 40MM ) to Ulur ($64 MM) . We'll be in the $20 soon.
The estimated market size for ACCP' MuGard(TM) in
the US exceeds $1 billion while ULUR ' market for oral pain relief in the United Kingdom is estimated at approximately $60 million.
I don't think Floyds was the big seller.The stock needs to weed out the overhang shares from the weak hands who bot right before the New Years when it ran from 5.4 to 7.4.IMO
OT ACCP -If you compare it(MC 40MM ) to Ulur ($64 MM) .
The estimated market size for ACCP' MuGard(TM) in
the US exceeds $1 billion while ULUR
' market for oral pain relief in the United Kingdom alone is estimated at approximately $60 million.